Glycopeptide antibiotics: Back to the future

Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program

(2014) R. E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cell permeable vanX inhibitors as vancomycin re-sensitizing agents

(2014) Ramaiah Muthyala et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

New Insights into Glycopeptide Antibiotic Binding to Cell Wall Precursors using SPR and NMR Spectroscopy

(2014) Juan Treviño et al.   CHEMISTRY-A EUROPEAN JOURNAL

Large-Scale Metagenomic-Based Study of Antibiotic Resistance in the Environment

(2014) Joseph Nesme et al.   CURRENT BIOLOGY

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

(2014) J.A. Roberts et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Human Cathelicidin LL-37 Resistance and Increased Daptomycin MIC in Methicillin-Resistant Staphylococcus aureus Strain USA600 (ST45) Are Associated with Increased Mortality in a Hospital Setting

(2014) G. Sakoulas et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Antibiotic resistance: An infectious arms race

(2014) Karyn Hede   NATURE

Transferable Vancomycin Resistance in a Community-Associated MRSA Lineage

(2014) Flávia Rossi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin

(2014) Mu Cheng et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Comprehensive Identification of Mutations Responsible for Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA)-to-VISA Conversion in Laboratory-Generated VISA Strains Derived from hVISA Clinical Strain Mu3

(2013) Miki Matsuo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Locations of the Hydrophobic Side Chains of Lipoglycopeptides Bound to the Peptidoglycan of Staphylococcus aureus

(2013) Sung Joon Kim et al.   BIOCHEMISTRY

Design, Synthesis, and Antibacterial Activity of Demethylvancomycin Analogues against Drug-Resistant Bacteria

(2013) Jun Chang et al.   ChemMedChem

Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections?

(2013) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)

(2013) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Developing new antibacterials through natural product research

(2013) Herbert A Kirst   Expert Opinion on Drug Discovery

The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA

(2013) Benjamin P. Howden et al.   INFECTION GENETICS AND EVOLUTION

Multicomponent antibiotic substances produced by fermentation: Implications for regulatory authorities, critically ill patients and generics

(2013) Adrian J. Brink et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Community-associated MRSA: What makes them special?

(2013) Michael Otto   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Antibiotics in the clinical pipeline in 2013

(2013) Mark S Butler et al.   JOURNAL OF ANTIBIOTICS

Glycopeptide antibiotic biosynthesis

(2013) Grace Yim et al.   JOURNAL OF ANTIBIOTICS

Probing the Role of the Vancomycin E-Ring Aryl Chloride: Selective Divergent Synthesis and Evaluation of Alternatively Substituted E-Ring Analogues

(2013) Joseph R. Pinchman et al.   JOURNAL OF MEDICINAL CHEMISTRY

First case of infection with vancomycin-resistant Staphylococcus aureus in Europe

(2013) José Melo-Cristino et al.   LANCET

Platforms for antibiotic discovery

(2013) Kim Lewis   NATURE REVIEWS DRUG DISCOVERY

Platelet-Type von Willebrand Disease: New Insights into the Molecular Pathophysiology of a Unique Platelet Defect

(2013) Harmanpreet Kaur et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Comparison of Six Generic Vancomycin Products for Treatment of Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis in Rabbits

(2012) P. Tattevin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and antibacterial activity against Clostridium difficile of novel demethylvancomycin derivatives

(2012) Si-Ji Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Current State of Clostridium difficile Treatment Options

(2012) A. A. Venugopal et al.   CLINICAL INFECTIOUS DISEASES

The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis

(2012) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

Screening Strategies to Identify New Antibiotics

(2012) Mark S. Butler et al.   CURRENT DRUG TARGETS

Overcoming the challenges to developing new antibiotics

(2012) David M Shlaes et al.   CURRENT OPINION IN PHARMACOLOGY

In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia

(2012) Kevin M. Krause et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011)

(2012) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Site-Selective Bromination of Vancomycin

(2012) Tejas P. Pathak et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Silver(I)-Promoted Conversion of Thioamides to Amidines: Divergent Synthesis of a Key Series of Vancomycin Aglycon Residue 4 Amidines That Clarify Binding Behavior to Model Ligands

(2012) Akinori Okano et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antibiotic resistance is ancient: implications for drug discovery

(2012) Gerard D. Wright et al.   TRENDS IN MICROBIOLOGY

Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300

(2012) Susana Gardete et al.   PLoS Pathogens

Structure of ristocetin A in complex with a bacterial cell-wall mimetic. Corrigendum.

(2011) Virginie Nahoum et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Generic Vancomycin Enriches Resistant Subpopulations of Staphylococcus aureus after Exposure in a Neutropenic Mouse Thigh Infection Model

(2011) Carlos A. Rodriguez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutation of RNA Polymerase β Subunit (rpoB) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3

(2011) Miki Matsuo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Antibiotics in the clinical pipeline in 2011

(2011) Mark S Butler et al.   JOURNAL OF ANTIBIOTICS

Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns

(2011) S. J. van Hal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study

(2011) Jun Yamakawa et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations

(2011) Natasha E. Holmes et al.   JOURNAL OF INFECTIOUS DISEASES

Synthesis and Stereochemical Determination of Complestatin A and B (Neuroprotectin A and B)

(2011) Steven P. Breazzano et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A Redesigned Vancomycin Engineered for Duald-Ala-d-Ala andd-Ala-d-Lac Binding Exhibits Potent Antimicrobial Activity Against Vancomycin-Resistant Bacteria

(2011) Jian Xie et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Total Synthesis of [Ψ[C(═S)NH]Tpg4]Vancomycin Aglycon, [Ψ[C(═NH)NH]Tpg4]Vancomycin Aglycon, and Related Key Compounds: Reengineering Vancomycin for Dual d-Ala-d-Ala and d-Ala-d-Lac Binding

(2011) Jian Xie et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antibiotic resistance is ancient

(2011) Vanessa M. D’Costa et al.   NATURE

A guiding hand for antibiotics

(2011) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator

(2010) O. Vesga et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

(2010) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates

(2010) Sebastiaan J. van Hal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Heteroresistance: a concern of increasing clinical significance?

(2010) M.E. Falagas et al.   CLINICAL MICROBIOLOGY AND INFECTION

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

New Lipoglycopeptides

(2010) George G. Zhanel et al.   DRUGS

Future challenges and treatment ofStaphylococcus aureusbacteremia with emphasis on MRSA

(2010) Rasmus V Rasmussen et al.   Future Microbiology

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

(2010) Emilio Bouza et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia

(2010) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Synthesis and Evaluation of Selected Key Methyl Ether Derivatives of Vancomycin Aglycon

(2010) Christine M. Crane et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Novel Series of Semisynthetic Vancomycin Derivatives Effective against Vancomycin-Resistant Bacteria

(2010) Yuki Nakama et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure of ristocetin A in complex with a bacterial cell-wall mimetic

(2009) Virginie Nahoum et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus

(2009) L. Cui et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies

(2009) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II

(2009) C. S. Lunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem

(2009) Y. Katayama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin

(2009) Katherine A. Lyseng-Williamson et al.   DRUGS

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

(2009) F. F. Arhin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years

(2009) A. C. Musta et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Diazo Transfer−Click Reaction Route to New, Lipophilic Teicoplanin and Ristocetin Aglycon Derivatives with High Antibacterial and Anti-influenza Virus Activity: An Aggregation and Receptor Binding Study

(2009) Gábor Pintér et al.   JOURNAL OF MEDICINAL CHEMISTRY

Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium

(2009) Gary J. Patti et al.   JOURNAL OF MOLECULAR BIOLOGY

Telavancin

(2009) G. Ralph Corey et al.   NATURE REVIEWS DRUG DISCOVERY

A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin

(2009) Michael T Guskey et al.   PHARMACOTHERAPY

Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Dalbavancin

(2008) Vanessa R Anderson et al.   DRUGS

Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus

(2008) Ian M. Gould   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions

(2008) Christopher Weidenmaier et al.   NATURE REVIEWS MICROBIOLOGY